P O O M ( 품 )

📍BP 106
📍Rx 29 KKU (Inter)
📍RxRama
📍Janssen
🚩 저는 태국 사람입니다.

[Shay Boloor @StockSavvyShay]

$SPCX successfully launched and deployed $ASTS BlueBird 8, 9 and 10 into orbit without issue.

Three more of the largest phased-array satellites ever deployed in LEO are now on their way to expanding AST SpaceMobile’s constellation.

[Noah Lindenberg, MD Oncologist-Hematologist @nlindenberg]

Toxicity is real and should be core component of shared decision making

[Henry C Fung| MM, lymphoma, leukemia & CART @HenrychihangFu1]

🦴 MajesTEC-4 (a post transplant maintenance trial) May Delay the Retirement of ASCT 😱

Fellow:

“Professor, with CARTITUDE-4, MajesTEC-3, MajesTEC-9, MonumenTAL-3, and future frontline studies such as MajesTEC-5/7, I think High-Dose Melphalan + AutoSCT will be honorably discharged soon!”

Professor:

“Not so fast.”

The updated MajesTEC-4 Safety Run-In (SRI) cohorts reported:

✅ Nearly 100% CR
✅ Nearly 100% MRD negativity
✅ Median PFS not reached
✅ Only 3 progressions reported

Importantly, MajesTEC-4 remains an ongoing Phase III study and the randomized portion is still actively enrolling.

Still, these data raise an interesting biological question.

For years, we viewed AutoSCT primarily as a delivery system for high-dose melphalan.

Perhaps it is more than that.

Perhaps HDM + AutoSCT serves as a platform for the next generation of immunotherapy through:

🦴 Deep cytoreduction

🦴 Marrow niche disruption

🧬 Immune ecosystem reset

🚀 An optimal setting for maintenance immunotherapy

First it was lenalidomide maintenance.

Now it may be teclistamab ± lenalidomide.

Whether this hypothesis is correct remains to be proven, but MajesTEC-4 certainly makes the discussion more interesting.

Perhaps AutoSCT is not the treatment.

🚀 Perhaps AutoSCT is the launchpad.

AutoSCT may stay around longer than me. 😄

#EHA2026 #Myeloma #Bispecifics

[Murali Janakiram @JanakiramMurali]

This is an important toxicity which we are working on in the IMWG. The real world patterns are not the same and we will present more data at ASH. Also a class effect seen with arlocel also . I will create a seperate thread on this - identification and management of this toxicity

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

#EHA2026

#nielsvandedonk MajesTEC-4 SRI data

At first glance, shocking that tec (bsAb) dose intensity so much higher than len dose intensity (~90% vs ~50%) 🤯

But honestly not surprising - len maintenance can be tough! Q4W tec with optimal supportive care quite maintainable.

[Al-Ola A Abdallah MD (USMIRC) @Abdallah81MD]

🚨 MonumenTAL-3 (NEJM 2026): Talquetamab Beats the Old Standard of Care… But the Biggest Question Wasn’t Answered! 🧵

Can Talquetamab Truly Move Earlier—and Where Does It Fit After BCMA-Directed Therapy? Let’s Discuss the Ups, Downs & Future.

1/ Talquetamab continues to reshape the RRMM landscape.

The Phase III #MonumenTAL3 trial compared:
✅ Talquetamab + Daratumumab + Pomalidomide (Tal-DP)
✅ Talquetamab + Daratumumab (Tal-D)
vs
✅ DPd

Patients had ≥1 prior line of therapy.

#mmsm #myeloma #MedEd #Mestwitter #USMIRC @US_HMC @USMIRCNEWS @MedwatchKate @Larvol @oncodaily

[Mark Wildgust (he/him) @MAWildgust]

Excited to see the #Monumental3 data being presented here @EHA_Hematology meeting #EHA2026 and now published in the @NEJM. Congratulations #PeterVoorhees.

https://t.co/1QPVeU9ffQ

[Georgia McCaughan @gjmccaughan]

MonumenTAL3 @PlasmaCellPete #EHA2026

RCT Tal-DP vs Tal-D vs DPd
RRMM. Median prior lines 2

Tal-DP & Tal-D sig. improved PFS.
2 year PFS: Tal-DP 81.3, Tal-D 77.6, DPd 51.2%

Weight loss stabilises after first 6m
Pts with 1+ grade 3 infection Tal-DP 37.7, Tal-D 29.2, DPd 42.4%

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

#EHA2026 plenary session 👏

MonumenTAL-3: Tal-Dara and Tal-DaraPom both beat Dara-Pd in terms of PFS and OS.

This is despite D-Pd doing the best it ever has (mPFS > 2 yrs).

BsAbs, both BCMA and GPRC5D, are here to stay in earlier lines for myeloma!

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

#EHA2026 Nice to work with @DrASRosenberg & elra team on this.

In brief, thanks to ∆ COVID and ⬆️ IVIG PPx, we're already seeing ⬇️ infections in RW setting with BCMA bsAbs in myeloma.

Still work to do: bacterial infxns, long-lasting URI/sinus infxns. But progress being made!

[Daniel Auclair @AuclairDan]

@bhemato updating here at #EHA26 #EHA2026 AZD0120 DURGA-1 FasTCAR study #mmsm

[Naveen Pemmaraju, MD @doctorpemm]

👏Fascinating talk by Professor Andrew Spencer from Australia 🇦🇺 at #EHA26 #EHA2026 on #InVivoCART #inMMyCAR first-in-human ph1 KLN-1010 for patients R/R MM #mmsm

[Murali Janakiram @JanakiramMurali]

Some of the most provocative q in IMWG- #IMWG26
- Do BsAb cause T cell exhaustion @NBahlis
-What needs to be done more than IVIG replacement to prevent infections in BsAb- @SagarLonialMD
-IEC colitis -@YiLinMDPhD @LMikkMD
- Benchmarks for subsequent T cell or non T cell based therapies
- Combination Rx for cure in NDMM - SR, HR and UHR @szusmani

[Eddie Cliff @Eddie_Cliff]

🚨 Hot off the press @NatRevClinOncol

In the wake of MajesTEC-9 presented at #ASCO26, we ask the provocative question: does cilta-cel have a future in myeloma?

https://t.co/ddjP5Xx4BC

What do you think?

#mmsm #myeloma #CARTcells @rajshekharucms @ManniMD1 @AlGarfall

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

Functional high-risk myeloma doesn’t know that we are earnestly gossiping about ways to define and end it here at #IMFIMWG2026 …

@End_myeloma @mbeksac56 @BrunoPaiva_UNAV just missing @MyMKaiser !

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#ASCO26 #mmsm

Some easy summary data for MajesTEC-9, really nice results and summary of adverse events

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#ASCO26 #mmsm Rapid oral myeloma

OPTec/Optal

✅Prophylactic Toci prior to SUd 1 or Tec or Tal reduced risk of CRS BY 5 folds

✅Really good strategy to prevent higher grade CRS and make those agents more community friendly

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#ASCO26 #mmsm
High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy
@DrGarethMorgan1

Summary of Phase 3 Randomized Trials in Early Line Relapse, Outcomes in Selected Populations

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#mmsm #IMWG26

TRIUMMpH trial design for high risk patients with myeloma which includes EMD

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#mmsm #IMWG26

German study using BsAb in NDMM👇